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Introduction: Whether the results of cancer clinical trials conducted 
outside the United States (USA) can be directly extrapolated to North 
American populations is a question of increasing importance due to 
recent trends toward globalization of the clinical trials process. Differ-
ences in outcomes between clinical trials evaluating the same treatment 
regimen can obviously be explained by many factors, including vari-
ance in patient demographics, trial design and conduct, and treatment 
itself. In regard to divergence of results in trials performed in different 
parts of the world, the additional question of racial and/our ethnic-re-
lated genetic differences must be considered. Approximately 7 years 
ago, the Southwest Oncology Group (SWOG) established an ongo-
ing collaboration with Japanese lung cancer investigators, in order to 
provide a forum for exchange of research data, to facilitate standariza-
tion of clinical trial design and conduct, and to establish areas for joint 
collaboration, as described below.
Purpose: To explore whether population-related pharmacogenomics 
contribute to differences in patient outcomes between clinical trials 
performed in Japan and the USA, given similar patient demographics 
and treatment.
Patients and Methods: We prospectively designed and conducted 
three phase III trials (FACS, LC03, S0003) in advanced stage NSCLC, 
with similar eligibility, staging and treatment with a “common arm” of 
paclitaxel-carboplatin. Genomic DNA was prospectively collected from 
patients in LC03 (N=78, 37 on common arm) & S0003 (N=78) receiv-
ing paclitaxel (225mg/m2) & carboplatin (AUC 6). Analysis for geno-
typic variants of CYP3a4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, 
ERCC2 was performed by pyrosequencing, & results assessed by Cox 
model for survival/PFS & logistics regression for response/toxicity.
Results: Clinical results were similar in the 2 Japanese trials, and 
signiﬁcantly different from the USA trial in survival, neutropenia, and 
febrile neutropenia. There was a signiﬁcant difference between Japan & 
USA patients in genotypes: CYP3A4*1b (p=.01), CYP3A5*3c (p=.03), 
ERCC2 k751q (p < .001), and CYP2C8 r139k (p=.01). Genotypic 
correlations were observed between CYP3A4*1b for PFS (HR 2.75, 
1.06-7.08, p=.04) & ERCC2 k751q for response (HR 0.33, 0.13-0.84, 
p=.02). There were no other statistically signiﬁcant associations. For 
grade 4 neutropenia, the HR for ABCB1 3425c->T was 1.84 (0.77-
4.48), p=.19. The low number of febrile neutropenia events within this 
data set precluded assessment of this parameter. 
Conclusions: Differences in allelic distribution for genes involved in 
paclitaxel disposition or DNA repair were observed between Japanese 
& USA patients. Genotype-associated correlations were present for 
PFS (CYP3A4*1b) & response (ERCC2 k751q), but not for neutrope-
nia (p=.19). The small sample size limits interpretation of these data. 
Further studies based on this common arm approach are warranted for 
the prospective study of population-related PGs where ethnical/racial 
differences in anti-neoplastic drug disposition are anticipated.
We hypothesized that population-related pharmacogenomics plays a 
role in explaining outcome differences between trials evaluating similar 
treatment regimens in advanced stage NSCLC demonstrate similarities 
or differences between patient characteristics and outcomes in Japanese 
and U.S. trials in advanced stage NSCLC under the inﬂuence of the 
same regimen. 
To provide the basis for standardization of study design and conduct in 
order to facilitate interpretation of future trials, and to provide the ﬁrst 
step to joint NCI sponsored studies in lung cancer between Japanese 
and U.S. investigators.
We have previously reported differences in outcomes (increased 
survival, neutropenia & febrile neutropenia) in Japanese versus US 
patients (pts) treated with a paclitaxel-carboplatin “common arm” in 
a prospectively designed fashion in 3 phase III trials (FACS, LC03, 
S0003) in advanced NSCLC (Gandara, ASCO 05 & Crowley, ASCO 
06). We hypothesized that these ﬁndings were due in part to PG altera-
tions in paclitaxel disposition.
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The JCOG 9511 study demonstrated that irinotecan + cisplatin therapy 
yielded signiﬁcantly better survival than etoposide + cisplatin in exten-
sive small cell lung cancer. On the other hand, Hanna reported no dif-
ference in response rate, median time-to-progression or overall survival 
in a second study that involved 331 ED-SCLC pts and compared two 
regimens, although irinotecan + cisplatin was given weekly. SWOG 
0124 used exactly the same schedule of administration of all anticancer 
drugs as JCOG 9511, and the toxicities in the 554 pts were compared 
with those of the patients in JCOG 9511. The results showed that the 
frequency of neutropenia, leucopenia, and anemia was signiﬁcantly 
higher in the JCOG 9511 patients.
Irinotecan + cisplatin is also one of the standard doublets used to treat 
NSCLC in Japan, and it yields a response rate, time to progression, and 
survival equivalent to other platinum doublets in NSCLC.
Topotecan is another topoisomerase I inhibitor. In a randomized trial in 
784 patients the combination of oral topotecan with cisplatin for 5 days 
was found not to be superior to etoposide and cisplatin. In the United 
States, topotecan has been used as a standard regimen for second line 
treatment of ED-SCLC. In Japan the JCOG just started an RCT of 
topotecan vs weekly irinotecan + etoposide + cisplatin.
Camptothecin analogues are detoxiﬁed by glucuronization. The SNP 
variability of UGT1A1 contributes to differences in the efﬁcacy or 
toxicity of cancer therapy. In the United States UGT1A1 PGx added “A 
reduction in the starting dose by at least one level should be considered 
